Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
ACADIA Pharmaceuticals Inc.'s (ACAD) Management Presents at 2020 Stifel Virtual Healthcare Conference (Transcript)
08:28pm, Tuesday, 17'th Nov 2020
ACADIA Pharmaceuticals Inc.'s (ACAD) Management Presents at 2020 Stifel Virtual Healthcare Conference (Transcript)
What's Behind Acadia Pharmaceuticals' Mixed Q3 Results
06:07am, Thursday, 05'th Nov 2020
The good news? Sales of Nuplazid are soaring.
ACADIA Pharmaceuticals Inc.'s (ACAD) CEO Steve Davis on Q3 2020 Results - Earnings Call Transcript
11:49pm, Wednesday, 04'th Nov 2020
ACADIA Pharmaceuticals Inc.'s (ACAD) CEO Steve Davis on Q3 2020 Results - Earnings Call Transcript
Why Acadia Healthcare Stock Is Soaring Today
01:48pm, Friday, 30'th Oct 2020
The company's latest quarterly update impressed investors.
Were Hedge Funds Wrong About Embracing ACADIA Pharmaceuticals Inc. (ACAD)?
10:02pm, Monday, 26'th Oct 2020
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-related p
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Morgan Stanley 18th Annual Global Healthcare Conference September 14, 2020 03:45 PM ET Company Participants Steve Davis - CEO Serge Stankovic - President Elen
ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020
01:00pm, Wednesday, 12'th Aug 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at The JMP Securities CNS Forum on Wednesday, August 19, 2020, at 11:00 a.m. Eastern Time.
Needham & Company LLC Reaffirms “Buy” Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)
07:58am, Sunday, 09'th Aug 2020
ACADIA Pharmaceuticals (NASDAQ:ACAD)‘s stock had its “buy” rating reissued by Needham & Company LLC in a report released on Thursday, TipRanks reports. They currently have a $60.00 price target
ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales
05:19pm, Thursday, 06'th Aug 2020
ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aileron Therapeutics
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates
10:25pm, Wednesday, 05'th Aug 2020
Acadia (ACAD) delivered earnings and revenue surprises of 38.64% and 4.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
08:05pm, Wednesday, 05'th Aug 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous syste
The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings
12:00am, Wednesday, 05'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
